Silkim Pharma developed a novel, protected PLATFORM of drugs for proven treatments of

multiple indications. 

 

Our PLATFORM is the result of extensive investigation of animal models of human diseases.

 

Members of our PLATFORM act as:

 

   (i) Potent anti-inflammatory agents,

   (ii) Strong iron chelating agents, and

   (iii) Anti-biotic agents. 

 

These Modes of Action jointly assist in treating the causes and/or symptoms of multiple indications.

 

Our PLATFORM enables accelerated expansion from one proven product to another without having to rediscover and re-create a specific underlying technology for each product.

 

Concenter BioPharma is committed to developing and delivering proven therapies that work harmoniously with the human body and advance the treatment landscape for people with life-threatening diseases.

 

Potential Clinical Applications include:

 

  • CNS Injury and Degenerative Diseases - demonstrated by enhanced recovery of Spinal Cord Injury (mouse); is expected to prove efficient in Multiple Sclerosis,  Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

  • Inflammatory skin disorders - extensively demonstrated efficient treatment of irritant contact dermatitis (mouse), and in sporadic human cases of psoriasis, seborrhea dermatitis, , wound healing, and chemical/heat burns.

  • Inflammatory Pulmonary diseases - demonstrated efficiency in the treatment of Ovalbumin-induced asthma model (mouse); is expected to show high efficiency in human asthma, nasal polyposis, allergic rhinitis, cystic fibrosis (CF), and lung fibrosis.

  • Type 2 diabetes and its complications - demonstrated in diet-induced diabetes (Sand Rat) by markedly inhibiting the appearance and the degree of hyperglycemia, arresting the conversion of insulin-resistance state to fully-blown diabetes; attenuating cataract formation and diabetes-induced retinopathy. Proved efficient on healing of diabetic foot ulcers (DFU) on human patients.

About Silkim Pharma Ltd.

Our Company

During the development of the PLATFORM the following milestones have already been realized:

 

  • Synthesis of several therapeutic agents – members of the PLATFORM

  • Chemical characterization of the structure and properties of the two therapeutic agents

  • Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of inflammatory skin diseases

  • Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of nutritionally induced diabetes

  • Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of asthma

  • Identification of molecular target of the therapeutic agents via 3 simultaneous modes of action

  • Identification of NEW members of the PLATFORM of therapeutic agents and partial characterization of their chemical properties and biological activities

  • Biological characterization of the therapeutic activities of the therapeutic agents in an animal model of spinal cord injury

  • 8 patents

Environment & Sustainability

© 2013 - 2019 Silkim Pharma Ltd. / Concenter BioPharma Ltd.

  • Facebook Clean
  • LinkedIn Clean
  • Twitter Social Icon